{"id":3797,"date":"2026-10-20T09:00:00","date_gmt":"2026-10-20T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3797"},"modified":"2026-10-20T21:02:49","modified_gmt":"2026-10-21T01:02:49","slug":"entinostats-china-phase-3-shows-pfs-benefit-without-confirmed-os-gain","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3797","title":{"rendered":"Entinostat\u2019s China Phase 3 Shows PFS Benefit Without Confirmed OS Gain"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

EOC Pharma<\/p>\n

Event Type<\/strong><\/p>\n

Peer-Reviewed Phase 3 Long-Term Follow-Up<\/p>\n

Modality<\/strong><\/p>\n

Small molecule; oral class I HDAC and HDAC4 inhibitor (with exemestane)<\/p>\n

Asset<\/strong><\/p>\n

Entinostat (plus exemestane)<\/p>\n

Target<\/strong><\/p>\n

Class I histone deacetylases; HDAC4<\/p>\n

Disease Area<\/strong><\/p>\n

HR-positive, HER2-negative advanced breast cancer<\/p>\n

Summary<\/h4>\n

Long-term results from a randomized, double-blind Phase 3 trial of entinostat plus exemestane in China showed median overall survival of 38.6 months versus 29.2 months for placebo plus exemestane, but the difference was not statistically significant (hazard ratio 0.83; 95% confidence interval 0.62\u20131.10; p=0.184). The peer-reviewed report was published online on 20 October 2026.<\/p>\n

The study had previously shown a statistically significant but modest progression-free-survival improvement and supported China’s 2024 approval of entinostat for hormone receptor\u2013positive, HER2-negative advanced breast cancer after endocrine therapy. The new analysis strengthens the description of post-progression treatment delay but does not confirm an overall-survival advantage. Direction is mixed, and global portability remains uncertain in a treatment landscape now shaped by CDK4\/6 inhibitors and additional targeted options.<\/p>\n

The multicenter trial enrolled 354 patients across 35 centers in China and randomized them 2:1 to entinostat plus exemestane or placebo plus exemestane. At a median follow-up of 31.8 months, median overall survival was 38.6 months in the entinostat arm and 29.2 months in the control arm. The hazard ratio favored entinostat numerically, but the confidence interval crossed one and the prespecified comparison was not significant.<\/p>\n

Median time to post-discontinuation chemotherapy was 11.7 months versus 6.8 months, and chemotherapy-free survival was 9.3 months versus 5.6 months; both comparisons were reported as statistically significant. Grade 3 or higher treatment-emergent adverse events occurred in 65.5% of patients receiving entinostat plus exemestane.<\/p>\n

The earlier primary analysis reported median progression-free survival of 6.32 months versus 3.72 months (hazard ratio 0.76; 95% confidence interval 0.58\u20130.98; p=0.046). China’s National Medical Products Administration approved entinostat in April 2024 for the relevant HR-positive\/HER2-negative advanced-breast-cancer setting.<\/p>\n

Deep Analysis<\/h4>\n

Entinostat inhibits class I histone deacetylases and HDAC4, altering chromatin accessibility and transcription. In endocrine-resistant breast cancer, the therapeutic thesis is that epigenetic reprogramming can restore hormone sensitivity or suppress resistance programs, allowing exemestane to regain activity. The randomized design and statistically significant PFS result establish drug activity in the studied population, but the absolute PFS gain was approximately 2.6 months.<\/p>\n

The favorable interpretation is that the total dataset is internally consistent: progression is delayed, chemotherapy is deferred and overall survival trends in the same direction. For patients seeking an oral, non-cytotoxic option, delaying chemotherapy may be meaningful even without a confirmed survival advantage. The large numerical OS difference also leaves open the possibility that the study was underpowered for survival or affected by subsequent-treatment crossover and heterogeneity.<\/p>\n

The competing interpretation is that a nonsignificant OS endpoint and high rate of severe adverse events limit the magnitude of benefit. The PFS p-value was close to the significance boundary, and the current global treatment sequence includes CDK4\/6 inhibitors, PI3K\/AKT\/mTOR pathway agents, oral SERDs and antibody\u2013drug conjugates. If relatively few trial participants received contemporary prior therapy, efficacy after current standards cannot be assumed.<\/p>\n

Regulatory portability therefore requires more than reproducing the China approval package. A globally relevant program would need transparent subgroup data by prior CDK4\/6 exposure, endocrine sensitivity, visceral disease and molecular alterations; standardized management of hematologic toxicity; and a comparator consistent with present practice. The paper is important on its own merits, but domestic approval does not automatically translate into international competitive positioning.<\/p>\n

Company and Product Background<\/h4>\n

EOC Pharma is a China-focused biopharmaceutical company developing and commercializing oncology therapies. Entinostat is an oral benzamide histone deacetylase inhibitor with activity against class I HDACs and HDAC4. By modifying chromatin regulation, the drug is intended to reverse or delay mechanisms of endocrine resistance.<\/p>\n

Hormone receptor\u2013positive, HER2-negative breast cancer is the largest molecular subtype of breast cancer. Advanced disease is generally managed through sequential endocrine-based combinations before chemotherapy, with treatment choice shaped by prior CDK4\/6 inhibition, actionable pathway alterations, endocrine sensitivity and disease tempo. Exemestane is a steroidal aromatase inhibitor that suppresses estrogen synthesis.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified fact:<\/strong> 354-patient randomized double-blind Phase 3 study across 35 Chinese centers.<\/li>\n
  • Verified fact:<\/strong> overall survival numerically favored entinostat but was not statistically significant (HR 0.83; p=0.184).<\/li>\n
  • Verified fact:<\/strong> earlier PFS analysis favored entinostat (6.32 versus 3.72 months; HR 0.76; p=0.046).<\/li>\n
  • Verified fact:<\/strong> grade 3 or higher treatment-emergent adverse events occurred in 65.5% of the combination arm.<\/li>\n
  • Interpretation A:<\/strong> consistent delay of progression and chemotherapy supports a clinically useful endocrine-resensitization option despite inconclusive OS.<\/li>\n
  • Interpretation B:<\/strong> borderline PFS, no confirmed survival benefit and toxicity reduce relevance against modern post-CDK4\/6 alternatives.<\/li>\n
  • Missing evidence:<\/strong> full contemporary-treatment exposure, post-progression therapy balance, quality-of-life outcomes and prospective performance after CDK4\/6 inhibitors.<\/li>\n
  • Upgrade trigger:<\/strong> validated benefit in a modern treatment sequence with biomarker-defined enrichment and manageable toxicity.<\/li>\n
  • Downgrade or falsifier:<\/strong> no benefit after CDK4\/6 therapy, unfavorable quality of life, or inability to identify a responsive subgroup.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The long-term dataset clarifies rather than transforms the asset. Entinostat has randomized evidence of disease-control benefit and delayed chemotherapy in the studied Chinese population, but the OS analysis does not establish survival improvement. The appropriate framing is a mixed clinical signal, not a failed study and not a global standard-setting result.<\/p>\n

    The strategic question is sequencing. China-originated data deserve evaluation on trial quality rather than geography, yet portability depends on whether the control arm and prior-therapy distribution match current practice elsewhere. The next value-inflecting evidence would be prospective efficacy after CDK4\/6 exposure and a biomarker that concentrates benefit enough to offset toxicity.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5 \u2014 mature randomized China Phase 3 follow-up for an approved epigenetic oncology drug, with direct implications for sequencing and portability. Signal Direction: Mixed \u2014 confirmed disease-control signal and chemotherapy delay, but no statistically significant overall-survival benefit and substantial severe toxicity. Confidence in Facts: High \u2014 peer-reviewed publication and regulator approval record are available. Confidence in Interpretation: Moderate \u2014 applicability to modern post-CDK4\/6 populations is not established. Red-team conclusion: the report does not infer that a numerical OS difference is causal or statistically proven and separates domestic evidence from global generalizability.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Long-term results from a randomized, double-blind Phase 3 trial of entinostat plus exemestane in China showed median overall survival of 38.6 months versus 29.2 months for placebo plus exemestane, but the difference was not…<\/p>\n","protected":false},"author":1,"featured_media":3803,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1121,1120,1122,1123,1107],"class_list":["post-3797","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-entinostat","tag-eoc-pharma","tag-hdac-inhibitor","tag-hr-positive-breast-cancer","tag-phase-3"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3797"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3797\/revisions"}],"predecessor-version":[{"id":3807,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3797\/revisions\/3807"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3803"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}